Spyre Therapeutics Inc. (SYRE) Stock Forecast & Price Target
Spyre Therapeutics Inc. · NASDAQ
$99.91-0.13 (-0.13%)
15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 12 firms covering Spyre Therapeutics Inc, 12 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $80.00 to $135.00, a moderate spread. The average target of $99.75 is roughly in line with the current $99.91. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.73 next quarter toward $-3.13 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS12 ratings
Strong Buy
Strong Buy18%
Buy1192%
Hold00%
Sell00%
Strong Sell00%
Based on 12 analysts giving stock ratings to Spyre Therapeutics Inc.
As of Jul, 12 of 12 firms rate SYRE a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
SYRE EPS & revenue forecast
EPS · NEXT QUARTER
$-0.73
Range $-1.02 – $-0.51 · 13 analysts · +384% YoY
Next period, 13 analysts expect Spyre Therapeutics Inc. to earn $-0.73 a share (range $-1.02 – $-0.51), versus $-0.15 a year earlier. Full-year consensus is $-2.95, growing to $-3.13 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 13 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Spyre Therapeutics Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on SYRE.
#1
Yatin Suneja
Guggenheim · Rank #28
Buy
$65.00-34.9% to target
Overall win rate
52%
+ Follow
#2
David Nierengarten
Wedbush · Rank #115
Buy
$100.00+0.1% to target
Overall win rate
41%
+ Follow
#3
Julian Harrison
BTIG
Buy
$112.00+12.1% to target
Coverage
—
+ Follow
#4
David Hoang
Deutsche Bank
Buy
$135.00+35.1% to target
Coverage
—
+ Follow
#5
Akash Tewari
Jefferies
Buy
$98.00-1.9% to target
Coverage
—
+ Follow
SYRE stock forecast FAQ
What is SYRE's average 12-month price target?+
The 12 analysts with a live target average $99.75 for Spyre Therapeutics Inc. over the next 12 months, ranging from a $135.00 high to a $80.00 low.
Is SYRE stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 12 analyst ratings, 12 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for SYRE?+
The Street-high target is $135.00 (Deutsche Bank), and the Street-low is $80.00 (Wedbush). The average of all 12 active targets is $99.75.
How many Wall Street analysts cover SYRE?+
12 analysts have an active rating on Spyre Therapeutics Inc., and 12 firms carry a live 12-month price target.
Who is the most accurate analyst covering SYRE?+
Among analysts who currently cover SYRE, Yatin Suneja of Guggenheim has the strongest overall Quantellect track record (Rank #28). Their current call is Buy with a $65.00 target.
What is Spyre Therapeutics Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.73 per share (range $-1.02 – $-0.51) across 13 analysts. Full-year EPS is projected at $-2.95, rising to $-3.13 the following year.
How much revenue is Spyre Therapeutics Inc. expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading SYRE lately?+
As of Jul, 12 of 12 firms rate SYRE a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their SYRE calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
